Skip to main content
Caplight Logo









Peptomyc

Peptomyc

Private
BarcelonaHealthcare & Life Scienceshttps://www.peptomyc.com/

Last Round

VC Round

Mar 24, 2024

Total Funding Raised

$24.69M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Peptomyc is a biotechnology company developing a new generation of cell-penetrating peptide therapeutics targeting the MYC oncogene for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

MYC inhibitorundruggable targetmini-protein therapeuticOMO-103targeted cancer therapydrugging the undruggablecell-penetrating peptideclinical-stage biotechoncology drug developmentOmomycsolid tumor therapypharmaceutical licensingPDAC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Peptomyc Comparables

Compare Peptomyc with similar companies based on industry and business-model similarity.

Peptomyc comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Incurix
77%
Omega Therapeutics
77%
Racura Oncology Ltd
77%

Peptomyc Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 24, 2024
GrantOct 31, 2023
Convertible DebtJan 20, 2022
VC RoundDec 15, 2020
Series ASep 12, 2019
Grant
Jul 30, 2019

Key People

Founding team and executive leadership

Laura Soucek

Founder and Chief Scientific Officer

Founding Team

Jesús Martin Garcia

Chief Executive Officer

Executive Team

Jörg Klumbis

CFO

Executive Team

Peptomyc Investors

Notable investors and investment history

Peptomyc investors
InvestorRounds
Asabys PartnersConvertible Debt
European Union's Horizon Research and Innovation programGrant
European Innovation Council FundVC Round, Grant
Alta Life SciencesConvertible Debt, VC Round, Series A
Healthequity SCRConvertible Debt, VC Round, Series A, Seed
Agencia Estatal de InvestigaciónDebt
EIT HealthGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 41% MoM.

  • Jul 26, 2026

    Monthly visitors increased 39% MoM.

Peptomyc Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Peptomyc Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Peptomyc's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range20
Year Founded2014
Last FundingMar 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?